The view
As of 13 November 2026, Ares Management closed at $134.61, a change of −9.7% over the past year, while the close sits +9.7% from its 200-day average and 43.9% above its 52-week low. No intrinsic value reading is published for this name today, so the price cannot be set against it here. The published 21-session view leans down, with an expected return of −0.51% and a probability of a rise of 19%. The published 63-session view also leans down, at −1.11%. The market regime is strong risk-off.
Next month: why the model view is negative
The published 21-session view leans down. The expected return of −0.51% is small, but the probability of a rise at 19% is low, inside a band from −19.9% to +18.9%. The strongest facts on that side are the strong risk-off market regime, short-sale volume at percentile 83 in the sector with crowding among the highest in the S&P 500, and a growth composite and momentum-factor sensitivity both at the lowest of the company's last five years. The history leans the other way. Of the 200 past situations like today's, the median move over the next 21 sessions was +1.5%, and 57% of them rose. That is history, matched on only seven measures, and it does not agree with the lean.
Next 3 months: model view negative
The published 63-session view also leans down, with an expected return of −1.11% inside a wide band from −25.3% to +23.1%. Both horizons point the same way. The facts behind that lean are a weak financial-health score of 2 out of nine and idiosyncratic volatility at the highest of the company's last five years. Several chart-pattern measures also sit at five-year extremes, including the longest stretch since a price spike or volume surge. The past situations again lean the other way. Across the 200 situations like today's, the median return over the next 63 sessions was +1.8%, and 55% rose. That history describes what followed similar setups and is not a forecast. It sits slightly against the model's lean.
The long term
The long-term case for Ares Management cannot rest on intrinsic value or on a sector valuation comparison, because neither is published for this name today. What remains is mixed. Revenue grew +9.2% over the past year and return on equity stands at 10.4%, a moderate level. Against that, the financial-health score is only 2, and the cash-flow payout ratio is the highest of the company's last five years, which leaves little cash flow retained. The history of the 200 past situations is more supportive: over the following year their median return was +10%, and 62% rose. The near-term views are driven by crowding, the regime and weak health signals, while the longer horizons rest on growth and that history.
How sure we are
Each horizon deserves limited weight. This name's own record is weak: of 283 matured 21-session forecasts, 38% matched the direction, below the base rate of about half across all names. That record argues for caution on the current downward lean. The history rests on 200 past situations, a reasonable sample, but it is matched on seven measures only and not on the full fingerprint. The bands are wide, from −19.9% to +18.9% over 21 sessions and from −25.3% to +23.1% over 63 sessions, so the central expectations are small relative to the range of outcomes.